共 50 条
- [1] Health-related quality of life and costs of receiving add-on therapy with insulin glargine or pioglitazone in patients with type 2 diabetes[J]. DIABETOLOGIA, 2006, 49 : 543 - 543Meneghini, L.Schwartz, S.Strange, P.Oster, G.
- [2] Pioglitazone (PIO) enhances insulin sensitivity (IS) in patients with type 2 diabetes (T2DM)[J]. DIABETES, 2002, 51 : A102 - A102Johns, DHerz, MTan, MHRobertson, KEGonzalez, BReviriego, JGrossman, LD
- [3] Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM)[J]. DIABETES, 2006, 55 : A111 - A111Fonseca, VivianDejager, SylvieAlbrecht, DiegoShirt, LyndaSchweizer, Anja
- [4] Efficacy and Safety of Colesevelam HCl (COL) as an Add-On to Pioglitazone (PIO) for Type 2 Diabetes Mellitus (T2DM)[J]. DIABETES, 2013, 62 : A273 - A273Ford, Daniel M.Baz-Hecht, MeravSaid, Nabil A.Tao, BenTruitt, Kenneth E.Chou, Hubert S.
- [5] Effect of Colesevelam HCl (COL) as an Add-On to Pioglitazone (PIO) on Lipid Particles in Type 2 Diabetes Mellitus (T2DM)[J]. DIABETES, 2013, 62 : A302 - A302Jones, Michael R.Ford, Daniel M.Baz-Hecht, MeravTao, BenTruitt, Kenneth E.Chou, Hubert S.
- [6] Insulin glargine (GLAR) improves health related quality of life (HRQOL) in patients with type 2 diabetes (T2DM) inadequately controlled on sulfonylurea plus metformin (SU plus MET)[J]. DIABETES, 2005, 54 : A142 - A142Vinik, AIDailey, GZhang, Q
- [7] Health-related quality of life (HRQL) of children and adolescents with type 1 (T1DM) or type 2 (T2DM) diabetes: The SEARCH for diabetes in youth study[J]. DIABETES, 2008, 57 : A273 - A273Naughton, Michelle J.Ruggiero, Andrea M.Lawrence, Jean M.Imperatore, GuiseppinaKlingensmith, Gerogeanna J.Waitzfelder, BethMcKeown, RoberteStandiford, Debra A.Liese, Angela D.Loots, Beth
- [8] Physician beliefs in efficacy of insulin glargine (GLAR) are associated with glucose control in type 2 diabetes (T2DM)[J]. DIABETOLOGIA, 2006, 49 : 527 - 528Herman, W.Zhang, Q.Kennedy, L.
- [9] Glycemic control achieved with insulin glargine (GLAR) as "Add-on" therapy in type 2 diabetes mellitus (T2DM) is unaffected by age, race, diabetes duration or BMI: The GOAL A1C study[J]. DIABETES, 2005, 54 : A141 - A141Kennedy, LHerman, WHHarris, AStrange, P
- [10] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Pioglitazone with or without Metformin in Patients with Type 2 Diabetes (T2DM)[J]. ENDOCRINE REVIEWS, 2014, 35 (03)Kovacs, Christopher SimonSeshiah, VeeraswamyMerker, LudwigChristiansen, Anita VedelRoux, FlavienSalsali, AfshinKim, GabrielStella, PeterWoerle, Hans-JuergenBroedl, Uli C.